17 December 2007

Trading Update : Progress in line with Expectations

Cyprotex PLC (“Cyprotex”) (AIM: CRX), the drug discovery technology and information company, announces a trading update for 2007.
Cyprotex is pleased to confirm that the closing months of 2007 have progressed along the lines intimated in Cyprotex’s trading update of 12 October 2007. Revenues are expected to fall between GBP3.6m and GBP3.7m, while current momentum suggests further progress will be made in the financial year 2008.

The final quarter of 2007 has been characterised by further expansion of the Group’s global customer base, along with the return to an excellent level of repeat business. Core customers continue to recognise the high level of ‘value-added’ within Cyprotex’s proprietary ADME/Tox (Absorption, Distribution, Metabolism, and Excretion/Toxicity) screening and consultancy services. Changes in the drug discovery world over the past twelve months highlight an increasing need by pharmaceutical majors for sophisticated and trusted outsourcing partnerships. Against this background, management recognises the opportunity for further significant expansion and enters the New Year on a confident note.

Despite incurring the costs of defending your Group from the ‘Requisitionists’ during the second half of the year, management is optimistic that it will end 2007 with a cash position similar to that seen at the interim stage. Importantly, Cyprotex expects to start 2008 with a total facility (cash plus unused overdraft) somewhat larger than at the same time last year.

For further information:
Cyprotex PLC
Robert Morrisson Atwater, CEO
Russell Gibbs, CFO
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Media Enquires:
WMC Communications
Alex Glover
Tel: +44 (0)20 7930 9030
alex.glover@wmccommunications.com